Share This Article:

Nimotuzumab in Treatment of Infiltrating Squamous Cell Carcinoma of Tongue

Abstract Full-Text HTML XML Download Download as PDF (Size:526KB) PP. 141-145
DOI: 10.4236/jct.2015.62015    5,471 Downloads   5,919 Views  
Author(s)    Leave a comment


A 50-year male patient presented to outpatient department with a mass on tongue associated with pain. A plain computerised tomography scan done on 17/01/13 revealed mild growth on lateral border of tongue with an enlarged jugulo-digastric lymph node measuring 1.8 × 1 cm. Excision of tongue was done and sent for histopathological examination which revealed infiltrating squamous cell carcinoma. The patient was treated with 2 cycles of Induction chemotherapy with cisplatin and paclitaxel administered in q3w schedule. Induction chemotherapy was followed by concurrent chemoradiotherapy with 6 cycles of nimotuzumab 200 mg and cisplatin 20 mg given weekly along with 60 gy/30 fractions of radiation using IMRT. Latest CT scan done on 20/01/2014 revealed no evidence of disease (NED).

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Prasad, A. (2015) Nimotuzumab in Treatment of Infiltrating Squamous Cell Carcinoma of Tongue. Journal of Cancer Therapy, 6, 141-145. doi: 10.4236/jct.2015.62015.


[1] Morestein, H. (1919) La Cure Radicale du Cancer de la Langue. Journal Chirurgie, 15, 221-252.
[2] Butlin, H.T. (1909) An Address on the Results of Operations for Carcinoma of the Tongue, with an Analysis of 197 Cases: Delivered before the International Surgical Society in Brussels. British Medical Journal, 1, 1.b2-1.b6.
[3] Douglas, Q., et al. (1921) Treatment of Carcinoma of the Tongue. Annals of Surgery, 73, 716-723.
[4] Globocan (2015) Fact Sheets by Population—Globocan—IARC.
[5] Iype, E.M., Pandey, M., Mathew, A., Thomas, G., Sebastian, P. and Nair, M.K. (2001) Squamous Cell Carcinoma of the Tongue among Young Indian Adults. Neoplasia, 3, 273-277.
[6] Ciardiello, F. and Tortora, G. (2008) EGFR Antagonists in Cancer Treatment. The New England Journal of Medicine, 358, 1160-1174.
[7] Akashi, Y., Okamoto, I., Iwasa, T., et al. (2008) Enhancement of the Antitumor Activity of Ionising Radiation by Nimotuzumab, a Humanised Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Non-Small Cell Lung Cancer Cell Lines of Differing Epidermal Growth Factor Receptor Status. British Journal of Cancer, 98, 749-755.
[8] Crombet, T., Torres, L., Neninger, E., et al. (2003) Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients with Advanced Epithelial-Derived Cancer. Journal of Immunotherapy, 26, 139-148.
[9] Crombet, T., Osorio, M., Cruz, T., et al. (2004) Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination with Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. Journal of Clinical Oncology, 22, 1646-1654.

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.